文献速递浆细胞疾病

初诊多发性骨髓瘤伴髓外病变患者的临床特征与结局比较

[Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该回顾性研究比较了80例初诊多发性骨髓瘤伴骨相关髓外(EM-B)与骨外髓外(EM-E)病变患者的临床特征及预后。结果显示EM-E组β2微球蛋白、乳酸脱氢酶、1q21扩增率和Ki-67指数更高,CD56阳性率和总有效率更低,中位OS和PFS显著缩短;蛋白酶体抑制剂诱导治疗可改善EM-E组PFS。

要点

  • EM-E组较EM-B组β2微球蛋白、LDH、1q21扩增率和Ki-67指数更高,CD56阳性率和总有效率更低。
  • EM-E组中位OS 14.5个月、PFS 9.0个月,均显著短于EM-B组的49.5个月和18.0个月。
  • 蛋白酶体抑制剂诱导治疗可改善EM-E组PFS,两组PFS差异无统计学意义(P=0.263)。

核心结论

  • 伴EM-E的NDMM患者与伴EM-B者临床特征及预后不同,前者预后明显更差。
  • 蛋白酶体抑制剂诱导治疗可改善EM-E组患者的PFS。

研究设计与样本

  • 回顾性分析2009年11月至2019年3月江苏省人民医院血液科诊治的80例伴髓外病变的NDMM患者。
  • 80例中伴EM-B者51例,伴EM-E者29例。

主要发现

  • EM-E组β2微球蛋白5.82 mg/L对3.99 mg/L(P=0.030),乳酸脱氢酶256 U/L对184 U/L(P=0.003)。
  • EM-E组1q21扩增率78.6%对53.1%(P=0.035),Ki-67增殖指数50%对25%(P=0.002)。
  • EM-E组CD56阳性率14.3%对66.7%(P=0.057),总有效率60.0%对82.3%(P=0.034)。
  • EM-E组与EM-B组中位OS分别为14.5和49.5个月,中位PFS分别为9.0和18.0个月。
  • EM-E组OS(P=0.035)和PFS(P<0.001)均显著短于EM-B组;接受蛋白酶体抑制剂诱导者两组PFS差异无统计学意义(P=0.263)。

关键数值与推荐

  • Cox多因素分析:诱导后最佳疗效未达PR是EM-E组OS(P=0.031)和PFS(P=0.005)的独立不良预后因素。
  • ISS-Ⅲ期(P=0.009)和诱导后最佳疗效未达PR(P=0.044)是EM-B组OS的独立不良预后因素。

临床怎么用

  • 对NDMM伴髓外病变患者应区分EM-B与EM-E,EM-E者需警惕预后不良。
  • EM-E患者诱导治疗可考虑含蛋白酶体抑制剂的方案以改善PFS。

局限性

  • 回顾性研究,样本量80例,EM-E组仅29例。
  • 单中心研究,结论需多中心验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To compare the clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma(NDMM)with bone-related extramedullary(EM-B)disease and those with extraosseous extramedullary(EM-E)disease and to address their prognostic factors. Methods: The clinical features, outcomes, and prognostic factors were retrospectively analyzed in 80 patients with NDMM with extramedullary disease. Results: Among 80 patients with extramedullary disease, 51 had EM-B and 29 EM-E. The level of β(2)-microglobulin(5.82 mg/L vs 3.99 mg/L, P=0.030), lactate dehydrogenase(256 U/L vs 184 U/L, P=0.003), 1q21 amplification rate(78.6% vs 53.1%, P=0.035), and Ki-67 proliferation index(50% vs 25%, P=0.002)in the EME group were significantly higher than those in the EM-B group. The posieive rate of CD56(14.3% vs 66.7%)and overall response rate(60% vs 82.3%)in EM-E group were significantly lower than those in EM-B group. The median overall survival (OS)of patients with EM-E and EM-B was 14.5 and 49.5 months, and the median progression-free survival(PFS)of the two groups was 9.0 and 18.0 months. Patients with EM-E had a significantly shorter OS(P=0.035)and PFS(P < 0.001)than those of patients with EM-B, whereas the PFS did not significantly differ(P=0.263)when patients accepted proteasome inhibitor(PI)-based regimens for induction therapy. Multivariate analysis with Cox model showed the best response that did not achieve partial response(PR)was an independent poor prognostic factor for both OS and PFS in NDMM patients with EM-E(P=0.031, P=0.005), ISS-III, and the best response that did not achieve PR were independent prognostic factors for the shorter OS in patients with NDMM with EM-B(P=0.009, P=0.044). Conclusions: The clinical characteristics and outcomes of patients with NDMM with EM-E are different from patients with EM-B. Outcomes of patients with EM-E is significantly poor. PI induction therapy improved the PFS of patients with EM-E. 目的: 比较伴骨相关髓外(EM-B)和骨外髓外(EM-E)病变的初诊多发性骨髓瘤(NDMM)患者的临床特征及预后,并探讨影响预后的因素。 方法: 回顾性分析2009年11月至2019年3月江苏省人民医院血液科诊治的80例伴髓外病变的NDMM患者的临床特征、预后及影响预后的因素。 结果: 80例累及髓外的NDMM患者中伴EM-B者51例,伴EM-E者29例。与EM-B组相比,EM-E组β(2)-微球蛋白水平(5.82 mg/L对3.99 mg/L,P=0.030)、乳酸脱氢酶水平(256 U/L对184 U/L,P=0.003)、1q21扩增发生率(78.6%对53.1%,P=0.035)、肿瘤细胞Ki-67增殖指数(50%对25%,P=0.002)升高,CD56阳性率(14.3%对66.7%,P=0.057)和治疗总有效率(60.0%对82.3%,P=0.034)降低。EM-E组和EM-B组的中位总生存(OS)时间分别为14.5、49.5个月,中位无进展生存(PFS)时间分别为9.0、18.0个月。与EM-B组患者相比,EM-E组患者的OS、PFS时间均明显缩短(P值分别为0.035和<0.001)。在接受蛋白酶体抑制剂诱导化疗的患者中,两组PFS时间的差异无统计学意义(P=0.263)。Cox回归多因素分析显示:诱导治疗后最佳疗效未达部分缓解(PR)是EM-E组患者OS、PFS的独立不良预后因素(P值分别为0.031、0.005);ISS-Ⅲ期、诱导治疗后最佳疗效未达PR为EM-B组患者OS的独立不良预后因素(P值分别为0.009、0.044)。 结论: 伴EM-E的NDMM患者与伴EM-B的患者有不同的临床特征及预后,前者的预后明显较后者差,蛋白酶体抑制剂可改善EM-E组患者的PFS。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang J, Zhang LN, Shi QL, et al. [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33190439. doi:10.3760/cma.j.issn.0253-2727.2020.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。